LINC Stock Overview
Linc AB is a private equity and venture capital firm, specializing in early, mid, late venture and mature stage investments in pharmaceutical, life-science and med-tech companies.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Linc AB Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr65.00 |
52 Week High | kr79.00 |
52 Week Low | kr52.20 |
Beta | 0.94 |
1 Month Change | 4.33% |
3 Month Change | 7.26% |
1 Year Change | 1.25% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -23.53% |
Recent News & Updates
Shareholder Returns
LINC | SE Capital Markets | SE Market | |
---|---|---|---|
7D | 6.7% | -8.0% | -1.6% |
1Y | 1.2% | 26.1% | 7.8% |
Return vs Industry: LINC underperformed the Swedish Capital Markets industry which returned 26.1% over the past year.
Return vs Market: LINC underperformed the Swedish Market which returned 7.8% over the past year.
Price Volatility
LINC volatility | |
---|---|
LINC Average Weekly Movement | 3.6% |
Capital Markets Industry Average Movement | 6.8% |
Market Average Movement | 6.1% |
10% most volatile stocks in SE Market | 12.8% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: LINC has not had significant price volatility in the past 3 months.
Volatility Over Time: LINC's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1991 | 2 | Karl Tobieson | linc.se |
Linc AB is a private equity and venture capital firm, specializing in early, mid, late venture and mature stage investments in pharmaceutical, life-science and med-tech companies. It prefers to invest in drug development usually take place at an early stage, while investments in medical technology are made in more mature businesses. The firm prefers to invest in Nordic companies.
Linc AB Fundamentals Summary
LINC fundamental statistics | |
---|---|
Market cap | kr3.76b |
Earnings (TTM) | kr401.01m |
Revenue (TTM) | kr384.44m |
9.4x
P/E Ratio9.8x
P/S RatioIs LINC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LINC income statement (TTM) | |
---|---|
Revenue | kr384.44m |
Cost of Revenue | kr0 |
Gross Profit | kr384.44m |
Other Expenses | -kr16.57m |
Earnings | kr401.01m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 6.92 |
Gross Margin | 100.00% |
Net Profit Margin | 104.31% |
Debt/Equity Ratio | 0% |
How did LINC perform over the long term?
See historical performance and comparison